336 related articles for article (PubMed ID: 33721882)
1. SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.
Wellens J; Colombel JF; Satsangi JJ; Wong SY
J Crohns Colitis; 2021 Aug; 15(8):1376-1386. PubMed ID: 33721882
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
Jørgensen KK; Høivik ML; Chopra A; Benth JŠ; Ricanek P; Moum PB; Jyssum I; Bolstad N; Warren DJ; Vaage PJT; Munthe PLA; Lundin PKEA; Anisdahl K; Syversen SW; Goll GL; Lund-Johansen F; Medhus AW; Jahnsen PJ
Scand J Gastroenterol; 2023; 58(8):874-882. PubMed ID: 36788656
[TBL] [Abstract][Full Text] [Related]
3. Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination.
Charilaou P; Tricarico C; Battat R; Scherl EJ; Longman RS; Lukin DJ
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):e1493-e1499. PubMed ID: 34896283
[TBL] [Abstract][Full Text] [Related]
4. Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.
Esposito S; Caminiti C; Giordano R; Argentiero A; Ramundo G; Principi N
Front Immunol; 2022; 13():933774. PubMed ID: 35812420
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
Lin S; Lau LH; Chanchlani N; Kennedy NA; Ng SC
Gut; 2022 Jul; 71(7):1426-1439. PubMed ID: 35477864
[TBL] [Abstract][Full Text] [Related]
6. Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease.
Kastl AJ; Weaver KN; Zhang X; Strople JA; Adler J; Kelsen JR; Dubinsky MC; Bousvaros A; Watkins R; Dai C; Cross RK; Higgins PDR; Ungaro R; Bewtra M; Bellaguarda EA; Farraye FA; Chun K; Zikry M; Bastidas M; Boccieri ME; Firestine A; Long MD; Kappelman MD
J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):871-877. PubMed ID: 38356293
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs.
Martínez-Domínguez SJ; García-Mateo S; Sainz-Arnal P; Martínez-García J; Gallego-Llera B; Lozano-Limones MJ; Hidalgo S; Gargallo-Puyuelo CJ; Latre-Santos M; Nocito-Colon MML; Martínez-Lostao L; Refaie E; Arroyo-Villarino MT; Del Rio-Nechaevsky M; Ramirez-Labrada A; Pardo J; Gomollón F; Baptista PM
Sci Rep; 2023 Dec; 13(1):23061. PubMed ID: 38155275
[TBL] [Abstract][Full Text] [Related]
8. Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease.
Frey S; Chowdhury R; Connolly CM; Werbel WA; Segev DL; Parian AM;
Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1609-1612.e1. PubMed ID: 34998996
[TBL] [Abstract][Full Text] [Related]
9. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
Doherty J; Fennessy S; Stack R; O' Morain N; Cullen G; Ryan EJ; De Gascun C; Doherty GA
Aliment Pharmacol Ther; 2021 Nov; 54(9):1110-1123. PubMed ID: 34472643
[TBL] [Abstract][Full Text] [Related]
10. Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study.
Elmahdi R; Ward D; Ernst MT; Poulsen G; Hallas J; Pottegård A; Jess T
BMJ Open; 2024 Feb; 14(2):e077408. PubMed ID: 38387988
[TBL] [Abstract][Full Text] [Related]
11. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic.
El Ouali S; Rubin DT; Cohen BL; Regueiro MD; Rieder F
Curr Opin Gastroenterol; 2021 Jul; 37(4):313-319. PubMed ID: 33859104
[TBL] [Abstract][Full Text] [Related]
12. Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis.
Woopen C; Schleußner K; Akgün K; Ziemssen T
Front Immunol; 2021; 12():701752. PubMed ID: 34234787
[TBL] [Abstract][Full Text] [Related]
13. Antibody, not Cellular, Immune Responses to SARS-CoV-2 Vaccination Outperform Infection in Inflammatory Bowel Disease Patients.
González Cueto E; Edmans M; Wellens J; Cadwell K; Thompson C; Satsangi J; Wong SY;
Inflamm Bowel Dis; 2024 May; 30(5):859-862. PubMed ID: 37935466
[No Abstract] [Full Text] [Related]
14. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician.
Chebli JMF; Queiroz NSF; Damião AOMC; Chebli LA; Costa MHM; Parra RS
World J Gastroenterol; 2021 Mar; 27(11):1022-1042. PubMed ID: 33776370
[TBL] [Abstract][Full Text] [Related]
15. The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy.
Li D; Xu A; Mengesha E; Elyanow R; Gittelman RM; Chapman H; Prostko JC; Frias EC; Stewart JL; Pozdnyakova V; Debbas P; Mujukian A; Horizon AA; Merin N; Joung S; Botwin GJ; Sobhani K; Figueiredo JC; Cheng S; Kaplan IM; McGovern DPB; Merchant A; Melmed GY; Braun J
Inflamm Bowel Dis; 2022 Jul; 28(7):1130-1133. PubMed ID: 35397000
[TBL] [Abstract][Full Text] [Related]
16. Cytokine signature in convalescent SARS-CoV-2 patients with inflammatory bowel disease receiving vedolizumab.
Dallari S; Martinez Pazos V; Munoz Eusse J; Wellens J; Thompson C; Colombel JF; Satsangi J; Cadwell K; Wong SY;
Sci Rep; 2024 Jan; 14(1):186. PubMed ID: 38168138
[TBL] [Abstract][Full Text] [Related]
17. Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study.
Zhang M; Huang Q; Shi C; Feng Y; Duan T; Lin T; Zhu Y; Liu G; Li H; Liu Y; Jiang B
Int J Colorectal Dis; 2023 Feb; 38(1):31. PubMed ID: 36757427
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association.
Costantino A; Noviello D; Conforti FS; Aloi M; Armuzzi A; Bossa F; Ficari F; Leone S; Manguso F; Mocci G; Orlando A; Pironi L; Radice S; Rizzello F; Tongiorgi A; Costantino C; Vecchi M; Caprioli F
Inflamm Bowel Dis; 2022 Mar; 28(3):474-478. PubMed ID: 34259844
[No Abstract] [Full Text] [Related]
19. Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study.
Macaluso FS; Principi M; Facciotti F; Contaldo A; Todeschini A; Saibeni S; Bezzio C; Castiglione F; Nardone OM; Spagnuolo R; Fantini MC; Riguccio G; Conforti S; Caprioli F; Viganò C; Felice C; Fiorino G; Correale C; Bodini G; Milla M; Scardino G; Vernero M; Desideri F; Bossa F; Guerra M; Ventimiglia M; Casà A; Rizzo G; Orlando A;
Inflamm Bowel Dis; 2024 May; 30(5):854-858. PubMed ID: 37390400
[No Abstract] [Full Text] [Related]
20. Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?
Scribano ML
Dig Dis Sci; 2021 Sep; 66(9):2855-2864. PubMed ID: 33073335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
